Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.77 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.77 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.77 |
| ▸ | ACHE | P22303 | 1/20 | 0.77 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.77 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.77 |
| ▸ | TOP1 | P11387 | 17/20 | 0.66 |
| ▸ | GLA | P06280 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27598514 | 1.00 | HTT (0.77) | HTTABCC3ABCC4ACHEPTGS1 | |
| SCHEMBL31091151 | 0.93 | HTT (0.76) | HTTABCC3ABCC4ACHEPTGS1 | |
| SCHEMBL6713165 | 0.93 | HTT (0.76) | HTTABCC3ABCC4ACHEPTGS1 | |
| SCHEMBL5547333 | 0.93 | HTT (0.75) | HTTABCC3ABCC4ACHEPTGS1 | |
| SCHEMBL8472836 | 0.91 | HTT (0.73) | HTTABCC3ABCC4ACHEPTGS1 | |
| SCHEMBL16521887 | 0.91 | HTT (0.72) | HTTABCC3ABCC4ACHEPTGS1 | |
| SCHEMBL4427322 | 0.90 | HTT (0.73) | HTTABCC3ABCC4ACHEPTGS1 | |
| SCHEMBL6848603 | 0.90 | HTT (0.74) | HTTABCC3ABCC4ACHEPTGS1 | |
| SCHEMBL6848262 | 0.89 | HTT (0.73) | HTTABCC3ABCC4ACHEPTGS1 | |
| SCHEMBL8814295 | 0.88 | HTT (0.70) | HTTABCC3ABCC4ACHEPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1480984-B9 | HEXACYCLIC COMPOUNDS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2009-03-11 | — | — | EP | disclosed |
| EP-1480984-B1 | CONDENSED CAMPTOTHECINS AS ANTITUMOR AGENTS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2008-06-11 | — | — | EP | disclosed |
| CN-100338066-C | Hexacyclic compounds | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2007-09-19 | — | — | CN | disclosed |
| CN-1911921-A | Method for identification of tumor targeting enzymes | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2007-02-14 | — | — | CN | disclosed |
| US-7109195-B2 | Hexacyclic compounds and their therapeutic use | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-09-19 | — | — | US | disclosed |
| CN-1617874-A | Hexacyclic compounds | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2005-05-18 | — | — | CN | disclosed |
| CN-1615131-A | Method for identifying tumor targeting enzyme | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2005-05-11 | — | — | CN | disclosed |
| US-20050059679-A1 | Novel hexacyclic compounds | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2005-03-17 | — | — | US | disclosed |
| EP-1492523-A2 | METHOD FOR IDENTIFICATION OF TUMOR TARGETING ENZYMES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-01-05 | — | — | EP | disclosed |
| EP-1480984-A2 | CONDENSED CAMPTOTHECINS AS ANTITUMOR AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-6825194-B2 | AN 11,12-(-N=C(=O,S OR NH)-NH-)CAMPTOTHECIN DERIVATIVE OR AN 11,12-(-N=CH-NH-)CAMPTOTHEDIN DERIVATIVE; ANTICARCINOGENIC, -TUMOR AND -PROLIFERATIVE AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-11-30 | — | — | US | disclosed |
| US-20030144304-A1 | Novel hexacyclic compounds | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-31 | — | — | US | disclosed |
| US-20030138864-A1 | Method for identifying an enzyme to design anti-cancer compounds | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-24 | — | — | US | disclosed |
| WO-2003045952-A2 | CONDENSED CAMPTOTHECINS AS ANTITUMOR AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-06-05 | — | — | WO | disclosed |
| WO-2003043631-A2 | METHOD FOR IDENTIFICATION OF TUMOR TARGETING ENZYMES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059679-A1 | Novel hexacyclic compounds | CYP11B1, CYP11B2, CYP4A11 | HTT 4042/4885ABCC3 952/4885ABCC4 746/4885 |
| US-20030138864-A1 | Method for identifying an enzyme to design anti-cancer compounds | RNASE1, GUSB, DPEP1 | HTT 4648/4885ABCC3 1848/4885ABCC4 2193/4885 |
| US-20030144304-A1 | Novel hexacyclic compounds | CYP11B1, CYP11B2, CYP51A1 | HTT 4198/4885ABCC3 748/4885ABCC4 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.